GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries

Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties.

GSK to purchase $9 million in shares of Spero common stock

LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license…


Source link

About search

Check Also

Chiefs' Wanya Morris, Chukwuebuka Godrick arrested for misdemeanor marijuana possession – Yahoo Sports

Chiefs' Wanya Morris, Chukwuebuka Godrick arrested for misdemeanor marijuana possession – Yahoo Sports

[unable to retrieve full-text content]Chiefs’ Wanya Morris, Chukwuebuka Godrick arrested for misdemeanor marijuana possession  Yahoo Sports …

Leave a Reply

Your email address will not be published. Required fields are marked *